| 摘要 |
<p>A method of controlling systemic copper levels in mammals includes administering to a mammal a compound which is preferentially bound by hepatocytes, serum albumin, or both, and which selectively binds with copper. The compounds can be administered to patients by oral or intravenous or topical routes in a phamaceutically acceptable vehicle, at a dosage which is dependent on the composition of the selected compound on the copper level, body weight of the patient or upon the surface area of skin being treated. The compounds of this invention have particular utility in the treatment of Wilson's Disease, angiogenic forms of cancer, psoriasis, and other pathologies in which angiogenesis causes or exacerbates the disease.</p> |
